The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Thoas Fioretos

Thoas Fioretos

Research team manager

Thoas Fioretos

A glioma classification scheme based on coexpression modules of EGFR and PDGFRA

Author

  • Yingyu Sun
  • Wei Zhang
  • Dongfeng Chen
  • Yuhong Lv
  • Junxiong Zheng
  • Henrik Lilljebjörn
  • Liang Ran
  • Zhaoshi Bao
  • Charlotte Soneson
  • Hans Olov Sjögren
  • Leif G. Salford
  • Jianguang Ji
  • Pim J. Frenc
  • Thoas Fioretos
  • Tao Jiang
  • Xiaolong Fan
Show all

Summary, in English

We hypothesized that key signaling pathways of glioma genesis might enable the molecular classification of gliomas. Gene coexpression modules around epidermal growth factor receptor (EGFR) (EM, 29 genes) or platelet derived growth factor receptor A (PDGFRA) (PM, 40 genes) in gliomas were identified. Based on EM and PM expression signatures, nonnegative matrix factorization reproducibly clustered 1,369 adult diffuse gliomas WHO grades II-IV from four independent databases generated in three continents, into the subtypes (EM, PM and EMlowPMlow gliomas) in a morphology-independent manner. Besides their distinct patterns of genomic alterations, EM gliomas were associated with higher age at diagnosis, poorer prognosis, and stronger expression of neural stem cell and astrogenesis genes. Both PM and EMlowPMlow gliomas were associated with younger age at diagnosis and better prognosis. PM gliomas were enriched in the expression of oligodendrogenesis genes, whereas EMlowPMlow gliomas were enriched in the signatures of mature neurons and oligodendrocytes. The EM/PM-based molecular classification scheme is applicable to adult low-grade and high-grade diffuse gliomas, and outperforms existing classification schemes in assigning diffuse gliomas to subtypes with distinct transcriptomic and genomic profiles. The majority of the EM/PM classifiers, including regulators of glial fate decisions, have not been extensively studied in glioma biology. Subsets of these classifiers were coexpressed in mouse glial precursor cells, and frequently amplified or lost in an EM/PM glioma subtypespecific manner, resulting in somatic copy number alteration-dependent gene expression that contributes to EM/PM signatures in glioma samples. EM/PM-based molecular classification provides a molecular diagnostic framework to expedite the search for new glioma therapeutic targets.

Department/s

  • Rausing laboratory of Lund - Tumor section
  • Division of Clinical Genetics
  • Centre for Mathematical Sciences
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • Family Medicine and Clinical Epidemiology

Publishing year

2014-03-04

Language

English

Pages

3538-3543

Publication/Series

Proceedings of the National Academy of Sciences of the United States of America

Volume

111

Issue

9

Document type

Journal article

Publisher

National Academy of Sciences

Topic

  • Cell and Molecular Biology

Status

Published

Research group

  • Rausing laboratory of Lund - Tumor section
  • Family Medicine and Clinical Epidemiology

ISBN/ISSN/Other

  • ISSN: 0027-8424